(-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.

Seventy-nine patients with idiopathic Parkinson's disease in various phases of evolution of the clinical picture were studied. All the patients, already under treatment with L-dopa + PDI, were treated with (-)deprenyl at the dose of 10 mg/day orally in two daily administrations. The mean follow-up was 8.7 months (range, 1-29). Overall, 47.6% of the patients improved, 27.4% showed a marked improvement, 38.1% showed evident modifications, and 27.4% worsened. Sixteen patients were excluded from the study for various reasons. In 53.2% of the cases it was possible to reduce the daily L-dopa dose by a mean of 30%. Overall, (-)deprenyl was effective in the treatment of our parkinsonian patients in the various conditions evaluated, and thus constitutes a new therapeutic strategy for Parkinson's disease.
AuthorsP Giovannini, E Martignoni, I Piccolo, C Pacchetti, M P Grassi, G Nappi, T Caraceni
JournalJournal of neural transmission. Supplementum (J Neural Transm Suppl) Vol. 22 Pg. 235-46 ( 1986) ISSN: 0303-6995 [Print] AUSTRIA
PMID3097258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Phenethylamines
  • Selegiline
  • Levodopa
  • Carboxy-Lyases
  • Adult
  • Aged
  • Carboxy-Lyases (antagonists & inhibitors)
  • Drug Therapy, Combination
  • Female
  • Humans
  • Levodopa (therapeutic use)
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy, physiopathology)
  • Phenethylamines (therapeutic use)
  • Selegiline (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: